Aplastic Anemia in Older Adults: How Age and Fitness Shape the Treatment Recommendation

The first clue was a sleeve of bruises on a forearm that had bumped nothing harder than a shopping cart. Then came the breathlessness on a single flight of stairs, and a nosebleed that would not quit. A retired teacher in her early seventies walks into a routine appointment expecting a vitamin deficiency and leaves with a referral to hematology and three words she has to look up: pancytopenia, bone marrow, aplastic.

Within days a new question crowds out the medical vocabulary. Someone in the family has read that transplant is the definitive treatment and that doctors reserve it for the young. So is she too old to be treated properly? That worry shapes how many people approach aplastic anemia treatment in older adults, and it rests on a misunderstanding.

Age is one factor the care team weighs. It is rarely the deciding one. What matters more is how robust the body is, how severe the marrow failure has become, and which options are realistically available. This article walks through how specialists make that call.

What actually happens in the bone marrow in aplastic anemia

Bone marrow is the spongy tissue inside large bones where blood is manufactured. A small pool of hematopoietic stem cells (the parent cells that can become any blood cell) churns out red cells to carry oxygen, white cells to fight infection, and platelets to plug leaks in blood vessels. In aplastic anemia that factory floor empties out. The stem cells are destroyed or stop dividing, and all three cell lines fall together, a pattern doctors call pancytopenia.

In most adults the damage is autoimmune: the body’s own T lymphocytes, a type of white cell, mistakenly attack the stem cells. According to the National Heart, Lung, and Blood Institute, the majority of cases have no identifiable trigger, though some follow exposure to certain medicines, industrial chemicals such as benzene, radiation, or a viral infection like hepatitis. It is not a cancer, even though it is often treated by the same specialists.

Diagnosis rests on a bone marrow biopsy, a sample taken from the back of the hip bone under local anesthetic. Under the microscope, normal marrow in a healthy young adult is crowded with developing cells; in aplastic anemia it is largely replaced by fat. Specialists grade severity by how empty the marrow looks and how low the blood counts have fallen. Mayo Clinic describes severe disease as marrow that is markedly reduced in cellularity alongside very low neutrophils, platelets and young red cells.

Severity is the first lever in every treatment decision because it dictates urgency. Mild or moderate disease may be watched with regular counts. Severe or very severe disease, especially with a neutrophil count low enough to leave the body nearly defenseless against bacteria, is treated as a medical emergency regardless of age.

Why aplastic anemia treatment for older adults weighs fitness over the calendar

Here is the idea worth holding onto: hematologists do not treat a birth certificate. They treat a person whose organs, muscle reserve and other illnesses together determine how much a given therapy can be tolerated.

Age still enters the equation, for two honest reasons. First, the most intensive treatment, a bone marrow (stem cell) transplant, requires conditioning chemotherapy and sometimes radiation to clear the way for donor cells, followed by months of immune suppression. Older bodies recover more slowly from that assault, and the risk of graft-versus-host disease, in which donor immune cells attack the recipient’s tissues, rises with age. Second, in people over about 60, a marrow that looks empty can occasionally be an early form of myelodysplastic syndrome, a group of disorders in which the marrow makes abnormal cells. Distinguishing the two changes the plan, so older patients often need extra genetic testing of the marrow sample before anything starts.

Fitness is assessed separately from chronological age. A 68-year-old who walks three miles daily, has well-controlled blood pressure and no diabetes may be a stronger candidate for intensive treatment than a 52-year-old with heart failure and kidney disease. Cleveland Clinic notes that the choice between transplant and medicine-based therapy depends on age, overall health and whether a matched donor exists; none of those stands alone.

This is also why the recommendation can change over time. If an older patient responds to immunosuppressive therapy, the question of transplant may never arise. If counts fail to recover, the same team may revisit transplant with fresh eyes, now armed with a clearer picture of how the person tolerated treatment so far. The plan is a conversation, not a verdict.

Severe aplastic anemia treatment options: the three main paths

For severe disease, specialists choose among three broad strategies, often layering them.

Immunosuppressive therapy aims to switch off the T-cell attack long enough for surviving stem cells to repopulate the marrow. The standard combination pairs antithymocyte globulin, an antibody preparation that depletes T cells, with cyclosporine, a medicine that blocks T-cell activation. It does not replace the marrow; it rescues what is left. This is the first-line route for most adults past their forties and for anyone without a suitable donor.

Stem cell transplant replaces the failed marrow with healthy stem cells from a donor, ideally a fully matched sibling. Mayo Clinic describes it as the treatment generally preferred for younger people who have a matched donor. It carries the heaviest short-term risks but, when it works, addresses the problem at its root rather than suppressing it.

Supportive care is not a lesser option; it is the floor beneath both of the others. Red cell transfusions relieve the fatigue and breathlessness of anemia, platelet transfusions reduce bleeding, and prompt antibiotics or antifungals treat infections that a depleted immune system cannot fight alone. For some frail older adults with serious coexisting conditions, well-organized supportive care may be the primary plan, chosen deliberately rather than by default.

A fourth element has moved from the margins toward the center: thrombopoietin receptor agonists, oral medicines that mimic a natural growth signal to stem cells. Specialists increasingly consider them alongside immunosuppression in severe disease. Each path is explored in its own section below, but the headline is simple. Older age narrows the transplant route and widens the role of medicine-based and supportive strategies, without closing any door by itself.

How immunosuppressive therapy for aplastic anemia works, step by step

Immunosuppressive therapy is the workhorse of aplastic anemia care in older adults, so it helps to understand what the two components actually do.

Antithymocyte globulin (ATG) is made by immunizing animals, usually horses, with human T cells and harvesting the resulting antibodies. Infused into a patient over several days in hospital, those antibodies bind to and destroy the T lymphocytes driving the autoimmune attack. Because it is a foreign protein, reactions are common: fever, chills, rash, and a delayed illness called serum sickness, with joint pain and fever appearing a week or two later. The team pre-treats with medicines to blunt these reactions and keeps the patient in hospital for monitoring.

Cyclosporine then takes over the longer job. Taken by mouth for many months, it interferes with the signaling T cells need to activate, holding the immune system in check while the marrow slowly refills. Its most watched side effects are rising blood pressure, strain on the kidneys, tremor, gum overgrowth and increased hair growth. Regular blood tests track kidney function and medicine levels, which matters more in older adults whose kidneys may already have less reserve.

Response is slow. Cleveland Clinic notes that blood counts may take several months to improve, and many centers judge the result at roughly 3–6 months. That delay is the hardest part for patients, who continue to need transfusions and infection precautions in the meantime. Some people respond partially, some fully, and a proportion do not respond or relapse later; the team may then consider a second course, a thrombopoietin receptor agonist, or transplant.

Nothing about this schedule is fixed. How long cyclosporine continues, how quickly it is tapered and whether any element is changed are decisions that belong to the prescribing hematologist, who adjusts to each person’s counts and side effects.

Is there a bone marrow transplant age limit for aplastic anemia?

People search for a single number, and there is not one. What exists is a sliding scale of risk that specialists translate into practice.

For decades, major hematology guidelines have recommended upfront transplant from a matched sibling for patients up to roughly age 40 with severe disease, and immunosuppressive therapy first for those older. Many centers now extend upfront transplant consideration to fit patients in their forties and into their fifties, particularly with a fully matched sibling donor. Beyond 60, transplant is uncommon as first treatment but is not unheard of as a second step after immunosuppression fails, especially when a careful assessment shows good organ function and little frailty.

Why the caution? Transplant in aplastic anemia differs from transplant for leukemia. The goal is not to kill cancer but to establish a new immune system without the old one rejecting it, so conditioning is designed to be less harsh. Even so, Mayo Clinic lists graft rejection, graft-versus-host disease and serious infection as the principal dangers, and all three climb with age and comorbidity. Older patients also more often have had many transfusions before transplant, which can sensitize the immune system and raise rejection risk.

Donor type matters as much as age. A matched sibling is preferred; a well-matched unrelated donor from a registry is the next option; half-matched (haploidentical) family donors, often a child of the patient, are increasingly used but add complexity. For an older adult, a healthy adult child as a haploidentical donor is sometimes the only realistic match, and the team weighs that against the added risks.

So the honest answer: there is no hard ceiling, only a rising bar. Whether an individual clears it is a judgment made jointly by the transplant and hematology teams after a formal fitness evaluation.

How doctors actually measure fitness before recommending treatment

Fitness in this context is not about gym membership. It is a structured attempt to predict how a particular body will cope with a particular treatment.

The first layer is a comorbidity count: diabetes, heart disease, lung disease, kidney function, liver function, prior cancers. Transplant teams often summarize these in a scoring system that assigns points to each condition and groups patients into low, intermediate and high risk. A single serious condition such as significant heart failure can outweigh a youthful appearance.

The second layer is performance status, a quick clinician rating of daily function from fully active to bedbound. It is crude but surprisingly predictive, and most teams require a good score before offering transplant.

The third layer, increasingly used for anyone over 65, is a geriatric assessment. This borrows tools from geriatric medicine: timed walking speed, grip strength, the ability to rise from a chair without using the arms, a brief cognitive screen, questions about falls, nutrition and mood, a review of every medicine taken, and a frank look at social support. Who will drive to twice-weekly transfusion appointments? Who will notice a fever at 2 a.m.? These are clinical variables, not afterthoughts.

Organ-specific tests round out the picture: an echocardiogram for heart pumping function, lung function tests, and blood tests of kidney and liver reserve. Cyclosporine in particular stresses the kidneys, so baseline kidney function helps the team anticipate how much room they have.

The outcome of all this is rarely a simple yes or no. More often it is a graded recommendation: transplant now, immunosuppression now with transplant held in reserve, or immunosuppression with supportive care as the main plan. The patient’s own priorities, including how much hospital time and risk they are willing to accept, are part of the data.

Aplastic anemia treatment in older adults at a glance

The table below summarizes how the main options tend to line up by age band and fitness. It describes typical practice patterns drawn from mainstream guidance; it is not a decision tool, and individual recommendations routinely depart from it.

Situation	Usual first approach	Held in reserve	Key considerations
Under ~40, severe disease, matched sibling donor	Stem cell transplant	Immunosuppressive therapy if no donor	Lowest transplant risk; aims to resolve the problem rather than suppress it
~40–60, fit, severe disease	Immunosuppressive therapy, often with a thrombopoietin receptor agonist; some centers offer upfront transplant with a matched sibling	Transplant if no response at about 3–6 months	Donor type, kidney and heart function, patient preference
Over 60, fit, severe disease	Immunosuppressive therapy plus supportive care	Transplant after careful fitness and geriatric assessment, usually only after failed medicine-based therapy	Exclude myelodysplastic syndrome first; cyclosporine kidney effects
Any age, frail or major comorbidity	Supportive care, with modified immunosuppression where tolerated	Reassessment if fitness improves	Transfusion access, infection plan, goals of care discussion
Any age, non-severe disease	Monitoring with regular counts	Treatment if counts fall or symptoms appear	Avoid marrow-suppressing medicines; watch for progression

Two patterns stand out. The 3–6 month window for judging immunosuppressive response, described by Cleveland Clinic as the period over which counts typically begin to recover, acts as a natural decision point across every adult age band. And in every row, supportive care appears, because transfusions and infection prevention are not alternatives to treatment but the scaffolding that makes treatment survivable.

Supportive care: transfusions, infection prevention and why they matter more with age

Supportive care is where most of an older patient’s time is actually spent, and it deserves more respect than the phrase suggests.

Red blood cell transfusions treat the symptoms of anemia: fatigue, breathlessness, dizziness, and in older adults with narrowed coronary arteries, chest pain. Hematologists set a threshold hemoglobin at which to transfuse, and that threshold is often individualized upward for people with heart disease. Repeated transfusions deposit iron in the liver and heart, so iron levels are tracked and iron-removing (chelation) medicines may be considered after many units, according to the National Heart, Lung, and Blood Institute.

Platelet transfusions reduce bleeding. They are typically given when the count falls very low or when there is active bleeding. Because transfused platelets last only days, a patient awaiting response to immunosuppression may need them weekly or more. Blood products are irradiated and filtered to reduce the risk of sensitizing the immune system, which matters if transplant remains a future possibility.

Infection is the chief danger when neutrophils are very low. Mayo Clinic advises that any fever in this situation is treated as an emergency with urgent intravenous antibiotics, often before the source is known. Many centers prescribe preventive antifungal and antiviral medicines during the deepest periods of neutropenia. Patients are taught to avoid crowds during peak respiratory virus seasons, to keep up with inactivated vaccines as advised (live vaccines are usually avoided during immune suppression), to practice careful hand hygiene and to have a thermometer at home.

Growth factors that stimulate white cell production are sometimes used short-term during infections, though they do not treat the underlying marrow failure.

For older adults, the logistics of supportive care are themselves a fitness question. Frequent hospital visits, intravenous access that may require a long-term line, and the vigilance needed for fevers all demand energy and help from others. Teams plan for that openly.

Where thrombopoietin receptor agonists fit in the plan

Thrombopoietin is the hormone that tells marrow to make platelets. Researchers discovered that medicines mimicking it, called thrombopoietin receptor agonists, do something unexpected in aplastic anemia: they appear to stimulate the hematopoietic stem cells themselves, not just platelet production, nudging a depleted marrow to regrow all three cell lines.

The best-studied of these in aplastic anemia is eltrombopag, an oral medicine. It was first evaluated in people whose disease had not responded to immunosuppressive therapy, then studied in combination with antithymocyte globulin and cyclosporine as initial treatment for severe disease. On the strength of that research, many specialist centers now include a thrombopoietin receptor agonist in first-line protocols, and the National Heart, Lung, and Blood Institute lists this class among the medicines used for aplastic anemia.

For older adults this option carries particular appeal because it is taken by mouth, does not require hospital admission on its own and does not add the transplant-type risks of conditioning or graft-versus-host disease. It is not free of concerns. The team monitors liver tests, watches for clotting events in people already prone to them, and repeats marrow examinations periodically because any medicine that stimulates stem cells raises a theoretical question about encouraging abnormal clones, the groups of genetically altered cells that can progress toward myelodysplastic syndrome. That surveillance is one more reason older patients receive genetic testing of the marrow at diagnosis and during follow-up.

A different thrombopoietin receptor agonist, romiplostim, given by injection, has also been studied. Which agent, if any, is appropriate, when it starts and how long it continues are questions for the prescribing hematologist. What patients can reasonably take from the evidence is that the medicine-based route has become broader and, for many older adults, is the main event rather than a consolation prize.

Aplastic anemia treatment for older adults: what the first weeks and months usually look like

Timelines vary, but a typical course of immunosuppressive therapy in an older adult follows a recognizable rhythm.

The first two weeks. Diagnosis is confirmed, marrow genetics are sent, and the fitness assessment described earlier is completed. Transfusions begin if counts are dangerously low. A central venous line may be placed. Antithymocyte globulin is given in hospital over several consecutive days with close monitoring for infusion reactions; cyclosporine starts around the same time. Most people spend one to two weeks as inpatients during this phase, though lengths of stay depend on complications.

Weeks two to six. Patients are usually home but tethered to the clinic. Serum sickness, if it occurs, tends to appear a week or two after antithymocyte globulin and is treated symptomatically. Blood counts are checked at least weekly. Transfusions continue because the marrow has not yet responded; this is the period when people most often feel discouraged, having undergone intensive treatment with no visible change. Infection precautions are at their strictest.

Months two to six. This is the window in which responses declare themselves. Cleveland Clinic notes that improvement in blood counts can take several months. The first sign is often a slowly rising reticulocyte count (young red cells), followed by platelets, with neutrophils lagging. Transfusion needs taper as counts climb. Cyclosporine side effects, especially blood pressure and kidney function, are watched closely in older adults.

Beyond six months. If a response is present, cyclosporine is usually continued and then tapered slowly over a period the hematologist sets, because stopping too quickly is linked to relapse. If there is no response, the team revisits options: a second course, adding or switching a thrombopoietin receptor agonist, or a formal transplant evaluation.

Every one of these intervals is a typical range, not a schedule. Individual courses are shaped by complications, response and the treating team’s judgment.

Aplastic anemia prognosis in elderly patients: what the evidence actually shows

Older adults and their families often read outcome statistics online and assume the numbers apply directly to them. Most of those statistics should be read with care, and some should be set aside entirely.

Several things are reasonably well established. Severe aplastic anemia left untreated carries a high risk of death from infection or bleeding within months, which is why specialists treat it urgently at every age. Treatment outcomes have improved substantially over the past few decades as supportive care, infection management and immunosuppressive regimens have matured; Mayo Clinic and the National Heart, Lung, and Blood Institute both describe the condition as treatable in most people with current approaches. And age is consistently associated with less favorable outcomes in published series, for the reasons already discussed: more comorbidity, slower recovery and the possibility of an underlying myelodysplastic process.

What the evidence does not support is a precise percentage that can be attached to any individual. Published figures come from study populations selected for fitness, treated at specialist centers, and often analyzed years ago with regimens that have since changed. Older patients were historically underrepresented in those trials, and those who were included tended to be fitter than average. A figure drawn from such a cohort says little about a specific 74-year-old with a specific kidney function and a specific donor situation.

A more useful way to think about prognosis in later life is in terms of modifiable factors. Prompt diagnosis before serious infection sets in, accurate exclusion of myelodysplastic syndrome, careful management of cyclosporine’s kidney effects, strong infection precautions during the months of neutropenia and consistent follow-up all shift the odds in a person’s favor, regardless of age. The treating team can and should discuss what response looks like for someone in your situation, but any honest answer will come with wide margins.

What people often get wrong about aplastic anemia in later life

A few misconceptions come up so often in clinic that they deserve direct correction.

“It is a type of leukemia.” It is not. Aplastic anemia is a failure of the marrow to produce cells, usually autoimmune in origin. Leukemia is an overproduction of abnormal cells. The two are treated by the same specialists and can occasionally be confused on an early marrow sample, which is why genetic testing matters, but they are different diseases.

“Over 60 means no real treatment.” Immunosuppressive therapy is given to people well into their seventies and sometimes beyond, and thrombopoietin receptor agonists have widened the medicine-based route further. Transplant is rarer at older ages, but the absence of transplant is not the absence of treatment.

“Iron tablets or a better diet will fix it.” Aplastic anemia is not caused by iron, vitamin B12 or folate deficiency, and taking supplements will not restore the marrow. In fact, repeated transfusions tend to overload the body with iron, so unsupervised iron supplements can do harm. MedlinePlus is clear that this condition requires specialist treatment, not dietary correction.

“If the counts come back, it is over.” Relapse can occur, particularly if cyclosporine is reduced too quickly, and a small proportion of people develop clonal disorders years later. Long-term follow-up with periodic marrow checks is standard, not excessive caution.

“Immunosuppression is the easy option.” It is less dangerous than transplant in the short term, but it demands months of transfusions, strict infection vigilance and tolerance of cyclosporine’s effects on kidneys and blood pressure. For an older adult living alone, that burden is real and is part of the fitness conversation.

“Sibling donors are automatic matches.” Each full sibling has roughly a one in four chance of being a full match. Many patients, especially from small families, have none.

Questions to ask your care team before deciding

A good consultation leaves room for the questions that matter to the person in the chair. These are the ones hematologists most often wish patients and families would ask.

• How severe is my disease by the standard criteria, and how urgent is the decision?
• Has myelodysplastic syndrome or another marrow disorder been excluded, and what genetic tests were sent on my marrow sample?
• Which treatment path are you recommending for me, and which of my health factors drove that recommendation?
• If immunosuppressive therapy is the plan, what side effects should I expect in the first month, and how will my kidneys and blood pressure be monitored?
• Would a thrombopoietin receptor agonist be part of my treatment, and what monitoring does it add?
• Have my siblings or children been tissue-typed, and is a transplant evaluation sensible now or only if medicine-based treatment does not work?
• At what point will you judge whether treatment has worked, and what happens if it has not?
• How often will I need transfusions, and how will I get to appointments if I feel unwell?
• Which vaccines should I have or avoid, and when?
• What should I do, and whom should I call, if I develop a fever at night or on a weekend?
• How will my other medicines, including over-the-counter pain relievers that can affect platelets, be reviewed?
• Is there a geriatric specialist or supportive care team involved, and can my family join these discussions?

Write the answers down or bring someone who will. Decisions in aplastic anemia are made over weeks, and the plan the team describes at diagnosis may evolve as test results and your response come in. Asking to revisit the plan at each milestone is not second-guessing; it is how good care works.

When to call your doctor: red-flag signs that cannot wait

Low blood counts leave very little margin for error, so the thresholds for seeking help are lower than for most illnesses. Call your hematology team’s urgent line, or go to the emergency department, if any of the following occur:

• A temperature of 100.4°F (38°C) or higher, even once and even if you feel well. Mayo Clinic advises treating fever during neutropenia as an emergency because infection can spread within hours.
• Shaking chills, sweats or feeling suddenly unwell without a fever, since some people on immune-suppressing medicines do not mount a temperature.
• Bleeding that will not stop after ten minutes of firm pressure, blood in urine or stool, black tarry stools, or coughing or vomiting blood.
• A sudden severe headache, confusion, weakness on one side, difficulty speaking or vision changes, which can signal bleeding in the brain when platelets are very low.
• Chest pain, pressure or new breathlessness at rest, which in anemia can mean the heart is struggling for oxygen.
• A rapidly spreading rash, widespread tiny red or purple dots on the skin, or new large bruises.
• Severe sore throat, mouth ulcers that prevent eating or drinking, or pain, redness or discharge around an intravenous line.
• Fainting, a racing heart or dizziness that does not settle on lying down.
• Markedly reduced urine output or swelling of the legs while taking cyclosporine, which can indicate kidney strain.

Less urgent but still worth a same-week call: a fall, a new medicine prescribed by another doctor, persistent nausea or tremor, or a planned dental procedure, which may need platelet support beforehand.

Keep a written list of your diagnosis, current medicines and the team’s contact numbers in your wallet or phone, and tell any clinician you see that you have aplastic anemia before they prescribe anything. When in doubt, call. The team would always rather hear from you unnecessarily than late.

Frequently asked questions

Is there an age limit for aplastic anemia treatment in older adults?

No. There is no upper age limit for treating aplastic anemia; immunosuppressive therapy and supportive care are offered at every age. What changes with age is the balance of risks for the most intensive option, stem cell transplant, which becomes less common as a first treatment beyond the fifties and is usually reserved for fit older adults whose disease has not responded to medicine-based therapy. The hematology team assesses fitness, not just age.

What is the usual bone marrow transplant age limit for aplastic anemia?

There is no fixed cutoff. Guidelines have historically favored upfront transplant from a matched sibling for severe disease in people under about 40, with immunosuppression first for those older. Many centers now consider transplant for fit patients into their fifties, and occasionally beyond 60 after a formal fitness and geriatric assessment, usually when immunosuppressive therapy has failed. Donor availability and organ function weigh as heavily as age.

How does immunosuppressive therapy for aplastic anemia work?

It suppresses the immune cells attacking the bone marrow so surviving stem cells can recover. Antithymocyte globulin, an antibody infusion given in hospital over several days, destroys T lymphocytes; cyclosporine, taken by mouth for many months, blocks T-cell activation to keep the attack from resuming. Blood counts typically take several months to improve, during which transfusions and infection precautions continue. The prescribing team sets all timing and adjustments.

What are the severe aplastic anemia treatment options if transplant is not suitable?

The main alternative is immunosuppressive therapy with antithymocyte globulin and cyclosporine, often combined with a thrombopoietin receptor agonist, an oral medicine that stimulates stem cells. Supportive care runs alongside: red cell and platelet transfusions, preventive and prompt treatment of infections, and sometimes iron-removing therapy after many transfusions. If a first course does not work, a second course or a later transplant evaluation may be considered.

What is the aplastic anemia prognosis in elderly patients?

Outcomes are generally less favorable with increasing age, mainly because of coexisting illnesses and slower recovery, but the condition is treatable in most people with current approaches according to mainstream sources. Published percentages come from selected study groups and should not be applied directly to any individual. Prompt diagnosis, exclusion of myelodysplastic syndrome, strong infection precautions and careful medicine monitoring all improve the outlook at any age.

How long does it take to know whether treatment has worked?

For immunosuppressive therapy, improvement in blood counts can take several months, and many teams make a formal assessment around 3–6 months, according to Cleveland Clinic. Reticulocytes and platelets usually recover before neutrophils. For transplant, donor cells typically begin producing blood within a few weeks, though full immune recovery takes much longer. These are typical ranges, and the treating team interprets each person’s results individually.

Can older adults with aplastic anemia stay on supportive care alone?

Yes, for some people this is a deliberate and reasonable plan. Frail older adults with serious heart, lung or kidney disease may not tolerate immunosuppressive therapy or transplant, and well-organized supportive care with transfusions, infection prevention and rapid treatment of fevers can maintain quality of life. The decision follows a goals-of-care discussion between the patient, family and hematology team, and it can be revisited if circumstances change.

Why do older patients need extra bone marrow tests before treatment?

Because an empty-looking marrow in someone over about 60 can occasionally be an early myelodysplastic syndrome, a disorder in which the marrow makes abnormal cells, rather than true aplastic anemia. The two look similar on a basic biopsy but are treated differently. Genetic and chromosomal tests on the marrow sample help distinguish them, and they are repeated during follow-up because clonal changes can emerge years later.

What side effects of cyclosporine matter most in older adults?

Kidney strain and raised blood pressure are the most closely watched, because older kidneys often have less reserve and many patients already take blood pressure medicines. Tremor, gum overgrowth, increased hair growth and raised potassium or magnesium changes can also occur. Regular blood tests track kidney function and medicine levels, and the hematologist adjusts treatment accordingly. Patients should never change how they take it without the prescribing team’s guidance.

What infections should someone with aplastic anemia watch for?

Bacterial infections are the main danger when neutrophils are very low, and fungal infections become a risk during prolonged neutropenia. Any fever of 100.4°F (38°C) or higher needs urgent medical attention, because infection can progress within hours. Hand hygiene, avoiding crowds during respiratory virus seasons, careful dental and skin care, and keeping inactivated vaccines current as advised all reduce risk. Live vaccines are usually avoided during immune suppression.

References

• Aplastic Anemia, National Heart, Lung, and Blood Institute (NIH)
• Aplastic Anemia, Cleveland Clinic
• Aplastic Anemia, MedlinePlus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.